{"entity":{"id":"upifitamab-rilsodotin","kind":"drug","name":"Upifitamab rilsodotin","aka":["XMT-1536","UpRi"],"tldr":"Upifitamab rilsodotin is an antibody-drug conjugate from Mersana Therapeutics, in registered phase 2 trials for ovarian cancer, non-small-cell lung cancer.","summary":"Upifitamab rilsodotin is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Mersana Therapeutics, in ovarian cancer, non-small-cell lung cancer. An antibody-drug conjugate: an antibody against a tumour surface protein carries a cytotoxic payload into the cell. The registry record does not state the target or payload; the trial entries below carry the sponsor's description. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Upifitamab rilsodotin","url":"https://clinicaltrials.gov/search?intr=Upifitamab%20rilsodotin"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["ovarian","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["mersana"],"institutions":[],"pathways":[],"terms":[],"trials":["nct03319628"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"modality":"Antibody-drug conjugate","mechanism":"An antibody-drug conjugate: an antibody against a tumour surface protein carries a cytotoxic payload into the cell. The registry record does not state the target or payload; the trial entries below carry the sponsor's description.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/upifitamab-rilsodotin/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"company":[{"id":"mersana","kind":"company","name":"Mersana Therapeutics","route":"/companies/mersana/"}],"trial":[{"id":"nct03319628","kind":"trial","name":"First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b","route":"/trials/nct03319628/"}]}}